Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 19031233 | COMPOUND WITH a-GLUCOSIDASE INHIBITORY ACTIVITY AND APPLICATION THEREOF | January 2025 | July 2025 | Allow | 5 | 1 | 0 | No | No |
| 17923250 | FLUORINE-CONTAINING PYRIMIDINE COMPOUND AND FLUORINE-CONTAINING PYRIMIDINONE COMPOUND | November 2022 | July 2025 | Allow | 32 | 0 | 0 | No | No |
| 17781839 | CRYSTAL FORM AS INHIBITOR OF ACC1 AND ACC2, AND PREPARATION METHOD THEREFOR AND USE THEREOF | June 2022 | December 2022 | Allow | 7 | 0 | 0 | No | No |
| 17677457 | METHODS FOR CONVERTING THC-RICH CANNABINOID MIXTURES INTO CBN-RICH CANNABINOID MIXTURES | February 2022 | August 2022 | Allow | 6 | 1 | 0 | No | No |
| 17634473 | PROCESS FOR THE PURIFICATION OF ORGANIC SULFUR COMPOUNDS | February 2022 | August 2022 | Allow | 6 | 0 | 0 | No | No |
| 17416918 | IMMUNITY MECHANISM AND THERAPEUTIC DRUG FOR GASTROINTESTINAL DISEASES | December 2021 | October 2025 | Abandon | 52 | 1 | 1 | No | No |
| 17616142 | PYRAZOLE AND IMIDAZOLE DERIVATIVES, COMPOSITIONS AND METHODS AS OREXIN ANTAGONISTS | December 2021 | September 2025 | Abandon | 46 | 1 | 1 | No | No |
| 17341420 | CRYSTAL FORM OF KEY INTERMEDIATE OF BRUTON TYROSINE KINASE (BTK) INHIBITOR AND PREPARATION METHOD THEREOF | June 2021 | September 2021 | Allow | 4 | 1 | 0 | No | No |
| 17338802 | CD73 INHIBITORS AND USES THEREOF | June 2021 | November 2022 | Allow | 17 | 0 | 0 | No | No |
| 17290894 | METHOD FOR PREPARING DISELENIDE COMPOUND | May 2021 | November 2022 | Allow | 18 | 0 | 0 | No | No |
| 17287138 | PROCESS FOR PREPARING GLYCOLIDE | April 2021 | October 2022 | Allow | 18 | 0 | 0 | No | No |
| 17226367 | Crystalline Eravacycline Bis-Hydrochloride | April 2021 | January 2023 | Abandon | 22 | 1 | 0 | No | No |
| 17283196 | THIOPHENE CARBOXAMIDE DERIVATIVE AND PLANT DISEASE CONTROL AGENT COMPRISING SAME | April 2021 | October 2022 | Allow | 19 | 1 | 0 | No | No |
| 17173832 | APOE4-TARGETED THERAPUTICS THAT INCREASE SIRT1 | February 2021 | November 2022 | Abandon | 22 | 1 | 0 | No | No |
| 17265939 | Method for Preparation of 1,4-Sorbitan | February 2021 | July 2021 | Allow | 5 | 0 | 0 | No | No |
| 17136473 | SOLID FORMS OF AN SGC STIMULATOR | December 2020 | September 2022 | Allow | 21 | 1 | 0 | Yes | No |
| 17124407 | CRYSTALLINE FORMS OF 5-CHLORO-N4-[-2-(DIMETHYLPHOSPHORYL) PHENYL]-N2-{2-METHOXY-4-[4-(4-METHYLPIPERAZIN-1-YL) PIPERIDIN-1-YL] PHENYL} PYRIMIDINE-2,4-DIAMINE | December 2020 | April 2022 | Allow | 16 | 0 | 0 | No | No |
| 16977437 | NON-FLUORESCENT RHODAMINES | November 2020 | June 2022 | Allow | 22 | 1 | 1 | No | No |
| 17046120 | Resveratrol-Piperazine Co-Crystals | October 2020 | August 2022 | Allow | 23 | 1 | 0 | Yes | No |
| 17031151 | METHODS FOR PREPARING A PURIFIED MAYTANSINOID CONJUGATE IN A SOLUTION | September 2020 | July 2022 | Allow | 21 | 1 | 0 | No | No |
| 17040245 | METHOD FOR PRODUCING SOLID DISPERSION CONTAINING NOBILETIN | September 2020 | October 2021 | Allow | 13 | 2 | 0 | Yes | No |
| 17021701 | PROCESS FOR PRODUCING PYRROLE COMPOUND | September 2020 | July 2022 | Allow | 22 | 0 | 1 | No | No |
| 17015431 | [18F]-LABELLED LACTATE DERIVATIVE AS PET RADIOTRACER | September 2020 | October 2021 | Allow | 14 | 1 | 0 | No | No |
| 17001332 | BRIGHT TARGETABLE RED CA2+ INDICATORS | August 2020 | August 2022 | Allow | 24 | 1 | 0 | Yes | No |
| 16986718 | 3-METHYLIDENEOXAN-4-ONE COMPOUNDS AND SUBSTITUTED DERIVATIVES THEREOF AS INHIBITORS OF TELOMERASE | August 2020 | July 2022 | Allow | 23 | 1 | 1 | No | No |
| 16965398 | ANTI-CANCER COMPOUNDS | July 2020 | May 2022 | Allow | 22 | 1 | 1 | Yes | No |
| 16930178 | DERIVATIVES OF KORORMICIN USEFUL AS ANTIBIOTICS | July 2020 | January 2022 | Allow | 18 | 0 | 0 | No | No |
| 16962184 | AGRICULTURAL CHEMICALS | July 2020 | May 2022 | Allow | 22 | 1 | 0 | No | No |
| 16923853 | NOVEL CARBAZOLE EHOP-016 DERIVATIVES AS ANTI-CANCER AND ANTI-MIGRATORY AGENTS | July 2020 | May 2022 | Allow | 23 | 2 | 1 | Yes | No |
| 16960796 | METHOD FOR PREPARING TOLIMIDONE ON LARGE SCALE | July 2020 | October 2021 | Allow | 16 | 0 | 0 | No | No |
| 16916845 | PRODRUGS OF ALPHA-KETOGLUTARATE, ALPHA-KETOBUTYRATE, ALPHA-KETOISOVALERATE, AND ALPHA-KETOISOHEXANOATE, AND USES THEREOF | June 2020 | August 2022 | Allow | 25 | 4 | 1 | Yes | No |
| 16771885 | PROCESS FOR PRODUCING GLYCEROL CARBONATE METHACRYLATE | June 2020 | October 2021 | Allow | 16 | 0 | 0 | Yes | No |
| 16761855 | NOVEL SUBSTITUTED BIARYL COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE (IDO) INHIBITORS | May 2020 | July 2022 | Allow | 26 | 2 | 1 | No | No |
| 16754870 | POLYMERIZABLE LIQUID CRYSTAL COMPOUND, POLYMERIZABLE COMPOSITION, POLYMER, RETARDATION FILM, METHOD FOR PRODUCING RETARDATION FILM, TRANSFER LAMINATE, OPTICAL MEMBER, METHOD FOR PRODUCING OPTICAL MEMBER, AND DISPLAY DEVICE | April 2020 | September 2022 | Allow | 29 | 1 | 0 | Yes | No |
| 16843408 | SPIRO-CONDENSED PYRROLIDINE DERIVATIVES AS DEUBIQUITYLATING ENZYMES (DUB) INHIBITORS | April 2020 | September 2021 | Allow | 18 | 0 | 1 | No | No |
| 16828412 | Simplified Structural Mimetics of AIPS as Quorum Sensing Inhibitors | March 2020 | September 2022 | Allow | 30 | 1 | 1 | No | No |
| 16648714 | CYCLOPROPYLPYRIDYL GROUP-CONTAINING BENZIMIDAZOLE COMPOUND OR SALT THEREOF, AGRICULTURAL AND HORTICULTURAL INSECTICIDE COMPRISING THE COMPOUND OR THE SALT, AND METHOD FOR USING THE INSECTICIDE | March 2020 | November 2021 | Allow | 20 | 1 | 0 | No | No |
| 16647313 | MICROBIOCIDAL QUINOLINE (THIO)CARBOXAMIDE DERIVATIVES | March 2020 | October 2021 | Allow | 19 | 1 | 0 | No | No |
| 16781106 | ALCOHOL DERIVATIVES AS KV7 POTASSIUM CHANNEL OPENERS | February 2020 | February 2022 | Allow | 24 | 1 | 1 | Yes | No |
| 16635346 | PROCESSES FOR PREPARING PYRROLIDINE COMPOUNDS | January 2020 | April 2022 | Allow | 26 | 0 | 0 | No | No |
| 16632180 | PESTICIDALLY ACTIVE THIOPHENE DERIVATIVES | January 2020 | July 2022 | Allow | 29 | 3 | 0 | Yes | No |
| 16738226 | DIARYL CARBONATE AND METHOD FOR PRODUCING THE SAME, AND METHOD FOR PRODUCING AN AROMATIC POLYCARBONATE RESIN | January 2020 | August 2021 | Allow | 19 | 1 | 1 | No | No |
| 16628609 | PESTICIDALLY ACTIVE HETEROCYCLIC DERIVATIVES WITH SULFUR CONTAINING SUBSTITUENTS | January 2020 | March 2022 | Allow | 27 | 1 | 1 | Yes | No |
| 16625320 | OXADIAZOLE COMPOUND AND FUNGICIDE FOR AGRICULTURAL AND HORTICULTURAL USE | December 2019 | March 2022 | Allow | 27 | 1 | 0 | No | No |
| 16620047 | USE OF AN AMPHIDINOL FOR ITS FUNGICIDAL AND/OR BACTERICIDAL ACTIVITY ON FUNGI, OOMYCETES AND/OR PATHOGENIC BACTERIA OF PLANTS AND CROP SEEDS | December 2019 | November 2021 | Allow | 23 | 1 | 1 | No | No |
| 16703974 | NLRP3 MODULATORS | December 2019 | March 2021 | Allow | 16 | 1 | 0 | No | No |
| 16619925 | PROCESS FOR PREPARING 3,4-DICHLORO-N-(2-CYANOPHENYL)-5-ISOTHIAZOLECARBOXAMIDE | December 2019 | September 2021 | Allow | 21 | 1 | 0 | No | No |
| 16614521 | USE OF AMINOMETHYLENECYCLOHEXANE-1,3-DIONE COMPOUND | November 2019 | August 2022 | Allow | 33 | 4 | 1 | Yes | No |
| 16614715 | SUBSTITUTED INDOLINE DERIVATIVES AS DENGUE VIRAL REPLICATION INHIBITORS | November 2019 | March 2021 | Allow | 15 | 1 | 0 | Yes | No |
| 16684283 | NITROGEN-CONTAINING CYCLIC ORGANOXYSILANE COMPOUND AND METHOD FOR PRODUCING THE SAME | November 2019 | January 2022 | Allow | 27 | 1 | 1 | Yes | No |
| 16682167 | PROCESS FOR RECOVERING ACETONITRILE FROM ACRYLONITRILE WASTE STREAMS | November 2019 | May 2021 | Allow | 18 | 1 | 0 | Yes | No |
| 16681516 | METHODS FOR FORMING ARYL CARBON-NITROGEN BONDS USING LIGHT AND PHOTOREACTORS USEFUL FOR CONDUCTING SUCH REACTIONS | November 2019 | April 2021 | Abandon | 17 | 0 | 1 | No | No |
| 16612680 | DIARYLUREAS AS CB1 ALLOSTERIC MODULATORS | November 2019 | April 2021 | Allow | 17 | 0 | 1 | Yes | No |
| 16675784 | BCL-XL Inhibitory Compounds and Antibody Drug Conjugates Including the Same | November 2019 | January 2023 | Abandon | 38 | 0 | 1 | No | No |
| 16611085 | FLUORESCENT POLYMERS FOR MONITORING ANTISCALANT CONCENTRATIONS IN INDUSTRIAL WATER SYSTEMS | November 2019 | November 2022 | Abandon | 37 | 1 | 0 | No | No |
| 16608744 | NEW BICYCLIC PYRAZOLE DERIVATIVES | October 2019 | April 2021 | Allow | 18 | 1 | 0 | No | No |
| 16607871 | HETEROARYLPHENYLAMINOQUINOLINES AND ANALOGUES | October 2019 | May 2022 | Allow | 31 | 3 | 1 | Yes | No |
| 16663291 | CINNAMALDEHYDE DERIVATIVE COMPOUNDS, AND METHODS OF USE FOR CINNAMALDEHYDE DERIVATIVE COMPOUNDS NICOTINE CESSATION | October 2019 | October 2021 | Allow | 24 | 2 | 1 | Yes | No |
| 16461828 | COMPOUND HAVING ANTICANCER ACTIVITY AND PREPARATION METHOD AND APPLICATION | October 2019 | March 2022 | Allow | 34 | 3 | 0 | Yes | No |
| 16654032 | 4-Pyridinylmethyl-Morpholine Derivatives and the use thereof as Medicament | October 2019 | June 2021 | Allow | 20 | 2 | 0 | Yes | No |
| 16653629 | SALTS OF A THIAZOLIDINONE COMPOUND, SOLID FORMS, COMPOSITIONS AND METHODS OF USE THEREOF | October 2019 | July 2021 | Allow | 21 | 1 | 1 | No | No |
| 16604208 | HETEROARYL RHEB INHIBITORS AND USES THEREOF | October 2019 | December 2021 | Allow | 27 | 2 | 1 | Yes | No |
| 16593143 | COMPOSITIONS AND METHODS COMPRISING A TRIARYL POLYAMINE | October 2019 | January 2022 | Allow | 28 | 2 | 0 | No | No |
| 16587688 | ANTIMICROBIAL COMPOUNDS AND NANOSTRUCTURES | September 2019 | July 2021 | Allow | 21 | 1 | 1 | Yes | No |
| 16586667 | COMPOSITIONS AND METHODS COMPRISING SUBSTITUTED 2-AMINOIMIDAZOLES | September 2019 | January 2022 | Allow | 27 | 2 | 1 | Yes | No |
| 16586088 | Monoacylglycerol Lipase Modulators | September 2019 | May 2021 | Abandon | 20 | 0 | 1 | No | No |
| 16583263 | 2-(3,4-DIHYDROXYPHENYL)ETHYL 3-HYDROXYBUTANOATE, COMPOSITION, AND METHOD FOR IMPROVING FUNCTION OF AORTIC ENDOTHELIAL CELL | September 2019 | January 2021 | Allow | 15 | 1 | 0 | No | No |
| 16498338 | CD73 INHIBITORS AND USES THEREOF | September 2019 | August 2021 | Abandon | 23 | 1 | 1 | No | No |
| 16493492 | NOVEL POLYMORPHS OF (5-[3-(3-HYDROXYPHENOXY)AZETIDIN-1-YL]-5-METHYL-2,2-DIPHENYLHEXANAMIDE HYDROCHLORIDE | September 2019 | August 2021 | Abandon | 23 | 1 | 1 | No | No |
| 16491444 | NOVEL PREPARATION METHOD FOR ANTI-GOUT DRUG LESINURAD, AND KEY INTERMEDIATE THEREOF | September 2019 | March 2021 | Abandon | 18 | 0 | 1 | No | No |
| 16560478 | DEUTERATED SECNIDAZOLE FOR USE IN THE TREATMENT OF BACTERIAL VAGINOSIS AND METHODS AND USES THEREOF | September 2019 | March 2022 | Abandon | 30 | 3 | 0 | Yes | No |
| 16489462 | USES OF PYRIMIDOPYRIMIDINONES AS SIK INHIBITORS | August 2019 | October 2021 | Allow | 25 | 1 | 1 | Yes | No |
| 16548303 | Salt Type And Crystal Type Of 4h-Pyrazolo [1, 5-Alpha] Benzimidazole Compound And Preparation Method And Intermediate Thereof | August 2019 | December 2020 | Allow | 16 | 1 | 0 | No | No |
| 16529504 | KAPPA OPIOID AGONISTS AND USES THEREOF | August 2019 | May 2021 | Allow | 21 | 2 | 0 | Yes | No |
| 16525319 | CRYSTAL FORMS OF TETRAHYDRO-N,N-DIMETHYL-2,2-DIPHENYL-3-FURANMETHANAMINE HYDROCHLORIDE, PROCESSES OF MAKING SUCH FORMS, AND THEIR PHARMACEUTICAL COMPOSITIONS | July 2019 | November 2020 | Allow | 16 | 1 | 0 | Yes | No |
| 16523979 | HETEROCYCLE COMPRISING TYROSINE KINASE INHIBITORS | July 2019 | June 2021 | Allow | 22 | 2 | 1 | Yes | No |
| 16481307 | THERAPEUTIC AGENT FOR LIVER DISEASES | July 2019 | February 2021 | Allow | 19 | 0 | 0 | Yes | No |
| 16517947 | THROMBOXANE RECEPTOR ANTAGONISTS | July 2019 | December 2020 | Allow | 17 | 1 | 0 | No | No |
| 16510531 | Flash and Glow 1,2-Dioxetanes | July 2019 | November 2021 | Abandon | 28 | 2 | 1 | No | No |
| 16508001 | TRIAZOLE DERIVATIVES AND THEIR USE AS PDE4 ACTIVATORS | July 2019 | July 2020 | Allow | 12 | 0 | 0 | Yes | No |
| 16460381 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | July 2019 | August 2022 | Allow | 38 | 2 | 1 | No | No |
| 16469735 | METHOD FOR THE CONTROL OF PLANT BACTERIAL DISEASES USING CARBOXAMIDE DERIVATIVES | June 2019 | December 2021 | Abandon | 31 | 2 | 0 | No | No |
| 16438517 | PROCESS FOR PREPARING ELECTRON DEFICIENT OLEFINS | June 2019 | September 2020 | Allow | 15 | 1 | 0 | No | No |
| 16432469 | BICYCLIC HETEROCYCLIC DERIVATIVES AS MNK1 AND MNK2 MODULATORS AND USES THEREOF | June 2019 | February 2021 | Allow | 20 | 1 | 1 | No | No |
| 16429988 | CRYSTALLINE FORMS OF 5-CHLORO-N4-[-2-(DIMETHYLPHOSPHORYL) PHENYL]-N2-{2-METHOXY-4-[4-(4-METHYLPIPERAZIN-1-YL) PIPERIDIN-1-YL] PHENYL} PYRIMIDINE-2,4-DIAMINE | June 2019 | September 2020 | Allow | 15 | 1 | 0 | Yes | No |
| 16464916 | POLYMORPHIC FORM OF SEPIAPTERIN | May 2019 | May 2021 | Allow | 24 | 2 | 0 | No | No |
| 16464606 | COMPOUND, RESIN, COMPOSITION, RESIST PATTERN FORMATION METHOD AND CIRCUIT PATTERN FORMATION METHOD | May 2019 | October 2022 | Abandon | 41 | 0 | 1 | No | No |
| 16463544 | HALOGENATED BENZOTROPOLONES AS ATG4B INHIBITORS | May 2019 | April 2020 | Allow | 11 | 0 | 0 | No | No |
| 16417901 | TYK2 INHIBITORS, USES, AND METHODS FOR PRODUCTION THEREOF | May 2019 | March 2021 | Allow | 22 | 2 | 1 | Yes | No |
| 16461825 | Factor XIIa Inhibitors | May 2019 | February 2021 | Allow | 21 | 2 | 0 | Yes | No |
| 16461086 | NOVEL AZETIDINE DERIVATIVES USEFUL AS MODULATORS OF CORTICAL CATECHOLAMINERGIC NEUROTRANSMISSION | May 2019 | September 2020 | Allow | 16 | 0 | 1 | No | No |
| 16409279 | HYDROGENATION REACTION CATALYST FOR 1,4-ANHYDROERYTHRITOL, METHOD FOR PRODUCING 3-HYDROXYTETRAHYDROFURAN, AND METHOD FOR PRODUCING 1,3-BUTANE DIOL | May 2019 | June 2020 | Allow | 13 | 0 | 1 | No | No |
| 16404255 | METHODS FOR FORMING ARYL CARBON-NITROGEN BOND USING LIGHT | May 2019 | May 2021 | Allow | 24 | 2 | 1 | No | No |
| 16401950 | COMPOSITIONS COMPRISING AN INTEGRIN INHIBITOR AND AGENTS WHICH INTERACT WITH A CHEMOKINE AND METHODS OF USE THEREOF | May 2019 | June 2021 | Abandon | 26 | 2 | 1 | No | No |
| 16399529 | NEUROACTIVE STEROIDS, COMPOSITIONS, AND USES THEREOF | April 2019 | May 2021 | Allow | 25 | 2 | 0 | Yes | No |
| 16394986 | NUCLEAR TRANSPORT MODULATORS AND USES THEREOF | April 2019 | May 2021 | Abandon | 25 | 1 | 1 | No | No |
| 16341124 | CRYSTALLINE FORMS OF 4-(2-((1R,2R)-2-HYDROXYCYCLOHEXYLAMINO)BENZOTHIAZOL-6-YLOXY)-N-METHYLPICOLINAMIDE | April 2019 | November 2020 | Allow | 19 | 1 | 0 | Yes | No |
| 16361832 | Inflammasome inhibition for the treatment of Parkinson's disease, Alzheimer's disease and multiple sclerosis | March 2019 | September 2021 | Allow | 30 | 3 | 1 | Yes | No |
| 16360763 | CRYSTALLINE FORMS OF TENOFOVIR ALAFENAMIDE | March 2019 | June 2020 | Allow | 15 | 4 | 0 | No | No |
| 16351809 | HDAC INHIBITORS AND USES THEREOF | March 2019 | March 2020 | Allow | 12 | 0 | 0 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner RODRIGUEZ-GARCIA, VALERIE.
With a 0.0% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is in the bottom 25% across the USPTO, indicating that appeals face significant challenges here.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 10.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner RODRIGUEZ-GARCIA, VALERIE works in Art Unit 1626 and has examined 440 patent applications in our dataset. With an allowance rate of 63.2%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 22 months.
Examiner RODRIGUEZ-GARCIA, VALERIE's allowance rate of 63.2% places them in the 23% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by RODRIGUEZ-GARCIA, VALERIE receive 1.32 office actions before reaching final disposition. This places the examiner in the 19% percentile for office actions issued. This examiner issues significantly fewer office actions than most examiners.
The median time to disposition (half-life) for applications examined by RODRIGUEZ-GARCIA, VALERIE is 22 months. This places the examiner in the 88% percentile for prosecution speed. Applications move through prosecution relatively quickly with this examiner.
Conducting an examiner interview provides a +36.7% benefit to allowance rate for applications examined by RODRIGUEZ-GARCIA, VALERIE. This interview benefit is in the 84% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 31.5% of applications are subsequently allowed. This success rate is in the 64% percentile among all examiners. Strategic Insight: RCEs show above-average effectiveness with this examiner. Consider whether your amendments or new arguments are strong enough to warrant an RCE versus filing a continuation.
This examiner enters after-final amendments leading to allowance in 52.6% of cases where such amendments are filed. This entry rate is in the 79% percentile among all examiners. Strategic Recommendation: This examiner is highly receptive to after-final amendments compared to other examiners. Per MPEP § 714.12, after-final amendments may be entered "under justifiable circumstances." Consider filing after-final amendments with a clear showing of allowability rather than immediately filing an RCE, as this examiner frequently enters such amendments.
When applicants request a pre-appeal conference (PAC) with this examiner, 66.7% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 52% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences show above-average effectiveness with this examiner. If you have strong arguments, a PAC request may result in favorable reconsideration.
This examiner withdraws rejections or reopens prosecution in 66.7% of appeals filed. This is in the 47% percentile among all examiners. Of these withdrawals, 75.0% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows below-average willingness to reconsider rejections during appeals. Be prepared to fully prosecute appeals if filed.
When applicants file petitions regarding this examiner's actions, 64.4% are granted (fully or in part). This grant rate is in the 69% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.
Examiner's Amendments: This examiner makes examiner's amendments in 5.9% of allowed cases (in the 88% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 1% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.